Hematopoietic stem cell transplantation for non-Hodgkin lymphoma

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Up-front rituximab-based chemotherapy has improved outcomes in non-Hodgkin lymphoma (NHL); refractory or relapsed NHL still accounts for approximately 18,000 deaths in the United States. Autologous hematopoietic stem cell transplantation (SCT) can improve survival in primary refractory or relapsed aggressive NHL and mantle cell lymphoma and in relapsed follicular or peripheral T-cell lymphoma. Autologous SCT as a consolidation therapy after first complete or partial remission in high-risk aggressive NHL, mantle cell lymphoma, and peripheral T-cell lymphoma may improve progression-free survival. Allogeneic SCT offers a lower relapse rate but a higher nonrelapse mortality resulting in overall survival similar to autologous SCT.

Original languageEnglish (US)
Pages (from-to)1073-1095
Number of pages23
JournalHematology/Oncology Clinics of North America
Volume28
Issue number6
DOIs
StatePublished - Dec 1 2014

Fingerprint

Hematopoietic Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Stem Cell Transplantation
Peripheral T-Cell Lymphoma
Mantle-Cell Lymphoma
Disease-Free Survival
Recurrence
Drug Therapy
Mortality
Therapeutics

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Autologous hematopoietic stem cell transplantation
  • Diffuse large B-cell lymphoma
  • Follicular lymphoma
  • Mantle cell lymphoma
  • Non-Hodgkin lymphoma
  • Peripheral T-cell lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Hematopoietic stem cell transplantation for non-Hodgkin lymphoma. / Bhatt, Vijaya R; Vose, Julie Marie.

In: Hematology/Oncology Clinics of North America, Vol. 28, No. 6, 01.12.2014, p. 1073-1095.

Research output: Contribution to journalReview article

@article{6612ea9431ba4875b24d0738e82da622,
title = "Hematopoietic stem cell transplantation for non-Hodgkin lymphoma",
abstract = "Up-front rituximab-based chemotherapy has improved outcomes in non-Hodgkin lymphoma (NHL); refractory or relapsed NHL still accounts for approximately 18,000 deaths in the United States. Autologous hematopoietic stem cell transplantation (SCT) can improve survival in primary refractory or relapsed aggressive NHL and mantle cell lymphoma and in relapsed follicular or peripheral T-cell lymphoma. Autologous SCT as a consolidation therapy after first complete or partial remission in high-risk aggressive NHL, mantle cell lymphoma, and peripheral T-cell lymphoma may improve progression-free survival. Allogeneic SCT offers a lower relapse rate but a higher nonrelapse mortality resulting in overall survival similar to autologous SCT.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Autologous hematopoietic stem cell transplantation, Diffuse large B-cell lymphoma, Follicular lymphoma, Mantle cell lymphoma, Non-Hodgkin lymphoma, Peripheral T-cell lymphoma",
author = "Bhatt, {Vijaya R} and Vose, {Julie Marie}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.hoc.2014.08.015",
language = "English (US)",
volume = "28",
pages = "1073--1095",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation for non-Hodgkin lymphoma

AU - Bhatt, Vijaya R

AU - Vose, Julie Marie

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Up-front rituximab-based chemotherapy has improved outcomes in non-Hodgkin lymphoma (NHL); refractory or relapsed NHL still accounts for approximately 18,000 deaths in the United States. Autologous hematopoietic stem cell transplantation (SCT) can improve survival in primary refractory or relapsed aggressive NHL and mantle cell lymphoma and in relapsed follicular or peripheral T-cell lymphoma. Autologous SCT as a consolidation therapy after first complete or partial remission in high-risk aggressive NHL, mantle cell lymphoma, and peripheral T-cell lymphoma may improve progression-free survival. Allogeneic SCT offers a lower relapse rate but a higher nonrelapse mortality resulting in overall survival similar to autologous SCT.

AB - Up-front rituximab-based chemotherapy has improved outcomes in non-Hodgkin lymphoma (NHL); refractory or relapsed NHL still accounts for approximately 18,000 deaths in the United States. Autologous hematopoietic stem cell transplantation (SCT) can improve survival in primary refractory or relapsed aggressive NHL and mantle cell lymphoma and in relapsed follicular or peripheral T-cell lymphoma. Autologous SCT as a consolidation therapy after first complete or partial remission in high-risk aggressive NHL, mantle cell lymphoma, and peripheral T-cell lymphoma may improve progression-free survival. Allogeneic SCT offers a lower relapse rate but a higher nonrelapse mortality resulting in overall survival similar to autologous SCT.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Autologous hematopoietic stem cell transplantation

KW - Diffuse large B-cell lymphoma

KW - Follicular lymphoma

KW - Mantle cell lymphoma

KW - Non-Hodgkin lymphoma

KW - Peripheral T-cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84912116077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912116077&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2014.08.015

DO - 10.1016/j.hoc.2014.08.015

M3 - Review article

C2 - 25459180

AN - SCOPUS:84912116077

VL - 28

SP - 1073

EP - 1095

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -